Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Merck & Co Inc in-licensed NMG313 in 2019 (renamed MK-3655) and has recently started recruiting pre-cirrhotic NASH patients, with or without diabetes, into a Phase 2b clinical study to analyze MK-3655 effects on NASH resolution without worsening of fibrosis, after 52 weeks of treatment (Figure 2 and Table 1)
Lofgren, L
Alhajahjeh, A
Elevated levels of pro-inflammatory cytokines, such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-), generate massive amounts of reactive oxygen species (ROS)
US$ 28.40
US$ 28.39
US$ 27.61
US$ 25.06
US$ 24.72
US$ 26.83
US$ 23.55
